05.10.2021

Crafting a Cure for Diabetic Neuropathic Pain, Molecule by Molecule (Published by NIH)

A team of scientists at Knopp Biosciences LLC is innovating treatments to manage neuropathic pain by aiming at its source — hyperactive nerve cells.

Read the entire article from the NIH here!

FacebookTwitterLinkedIn

Keep reading

09.07.21

Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Discover this News

05.17.21

Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Discover this News

05.13.21

Knopp Biosciences to Present Details of Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Discover this News

01.14.21

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Discover this News

11.11.20

Knopp Biosciences Completes Class C Financing and Elects David Adair to Board of Managers

Discover this News